Key facts
| Company | MantroForce |
|---|---|
| FDA office | Center for Drug Evaluation and Research (CDER) |
| Letter date | June 17, 2026 |
| Subject / product | Unapproved New Drugs/Misbranded |
| CFR citations | FDA Warning Letter |
| Response due | 15 working days from receipt (standard FDA warning-letter requirement) |
| Reference / source ID | mantroforce-729021-06172026 |
Violations explained
FDA Warning Letter — Violations FDA cited at MantroForce
WARNING LETTER MantroForce MARCS-CMS 729021 — June 17, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: MantroForce Room 701, Unit 127, 7/F Tower B New Mandarin Plaza Tsim Sha Tsui Hong Kong SAR China info@mantroforce.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 17, 2026 WARNING LETTER Reference Number: 729021 To MantroForce: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Review Violations were identified and documented during a review of your website https://mantroforce.com/en-us in May 2026. Based on our review, “Passion Pro Endurance Delay Spray,” “Complex Men’s Nasal Inhaler,” “ErectBoost Vitality Spray for Men,” “Prostate Care Gel,” and “Prostate Patches” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an allinclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website, “Passion Pro Endurance Delay Spray,” “Complex Men’s Nasal Inhaler,” “ErectBoost Vitality Spray for Men,” “Prostate Care Gel,” and “Prostate Patches” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following: Passion Pro Endurance Delay Spray On the webpage https://mantroforce.com/en-us/products/long-lasting-confidence-delay-spray: “Master Your Performance and Last 5x Longer Starting Tonight” “IS PREMATURE EJACULATION DISRUPTING YOUR INTIMACY?” “FOR LONGER LASTING PERFORMANCE” “Why Choose Biancat™ Passion Pro Endurance Delay Spray? ✓ Extended Pleasure ✓ Delayed Climax ✓ Premature Control ✓ Optimized Sensitivity ✓ Intense Satisfaction” Complex Men’s Nasal Inhaler On the webpage https://mantroforce.com/en-us/products/men-nasal-inhaler-get-a-rock-harderection-within-5-minutes-100-without-pills: “Designed to combat slow, weak erections and performance anxiety, it offers fast results, without pills or risks.” “Men Nasal Inhaler Get a rock-hard erection within 5 minutes, 100% without pills!” “Experience the Powerful Erection Boost” “APPLICABLE TO THE FOLLOWING GROUPS WITH MALE PROBLEMS. . .PREMATURE EJACULATION[,] DECREASED LIBIDO” ErectBoost Vitality Spray for Men On the webpage https://mantroforce.com/en-us/products/vitality-spray-instant-power-get-a-rocksolid-erection-in-3-minutes-flat-copy: “ErectBoost Explosive Performance and Rock-Solid Power in 3 Minutes Flat” “Discover the ultimate solution for impotence with Vitality Spr
What happens next
MantroForce is expected to respond to FDA in writing, typically within 15 working days of the letter date, describing the specific corrective and preventive actions taken or planned for each violation cited. FDA reviews that response and any follow-up evidence, and can conduct a re-inspection to confirm the corrections were actually made. If FDA judges the response inadequate, or the underlying conditions serious enough, further action can follow, including product seizure, injunction, import alert, or civil penalties; many Warning Letters are resolved through corrective action alone. This page reflects the Warning Letter as issued and will not reflect any subsequent correction unless FDA publishes a follow-up record. FDA issues Warning Letters after an inspection or other review when it believes a firm has significantly violated FDA regulations; the letter itself is a notice, not a final adjudication.
MantroForce’s FDA history
Argus HQ has recorded 1 total FDA action tied to MantroForce: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.
Full letter text
Read the rest of the full text
Frequently asked questions
- What is an FDA Warning Letter?
- An FDA Warning Letter notifies a company that FDA believes it has significantly violated FDA regulations and that prompt corrective action is required. It is issued after an inspection, sample analysis, or other FDA review, and is a notice -- not a final legal determination and not itself a penalty.
- Does this Warning Letter mean MantroForce violated the law?
- FDA's letter documents violations it believes it found at MantroForce. A Warning Letter is not a final adjudication of guilt; the company has an opportunity to respond and correct the cited issues, and many Warning Letters are resolved without further enforcement once FDA confirms adequate correction.
- What happens after a Warning Letter is issued?
- The firm generally must respond in writing within 15 working days; FDA reviews the response and can escalate to seizure, injunction, or import alert if it judges the response inadequate. Many Warning Letters are resolved through corrective action alone.
- Has MantroForce had other FDA enforcement actions?
- This is the only FDA action Argus HQ has on file for MantroForce so far. Argus ingests new FDA enforcement records daily.
Get the next warning letter in this therapeutic area before your team hears about it secondhand.
Weekly briefing, free. Upgrade any time for daily or real-time delivery.
Related enforcement actions
Full FDA history for MantroForce- Warning letter (recent): Med Shop Inc / www.medshopinc.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): ketaminetroches.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketdaxandrugs / www.ketdaxandrugs.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Legit Ketamine Suppliers / www.legitketaminesuppliers.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Store / www.ketaminestore.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Buy Keta Online / www.buyketaonline.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Troche Store / www.ketaminetrochestore.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): All Ketamine HCL / www.allketaminehcl.com — Unapproved New Drugs/Misbranded (2026-06-23) →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). MantroForce — FDA Warning Letter, June 17, 2026: Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/warning-letter/mantroforce-729021-2026-06-17
"MantroForce — FDA Warning Letter, June 17, 2026: Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/warning-letter/mantroforce-729021-2026-06-17.
Argus HQ Research. "MantroForce — FDA Warning Letter, June 17, 2026: Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/warning-letter/mantroforce-729021-2026-06-17.
@misc{argushq_argushq_ai_warning_letter_mantroforce_729021_2026_06_17_2026,
title = {MantroForce — FDA Warning Letter, June 17, 2026: Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/warning-letter/mantroforce-729021-2026-06-17},
note = {Accessed: July 13, 2026}
}Source: FDA.gov — Warning Letters ↗

